Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2024 07:00 ET | Source: ARMGO

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies Phase 1b open label trial confirms safety and tolerability of 120...
January 29, 2024 01:00 ET | Source: ARMGO

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies Phase 1b open label trial confirms safety and tolerability of 120...
December 20, 2021 07:00 ET | Source: ARMGO

ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases

ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases Series B investment led by Forbion and joined by Pontifax and Kurma...